China’s COVID-19 vaccine found safe in the early stages of clinical trial: Study
A Chinese experimental COVID-19 vaccine which is being developed by the Institute of Medical Biology under the Chinese Academy of Medical Sciences was found to be safe in the early stages of clinical trial, according to researchers.
According to a paper posted on medRxiv preprint server ahead of peer review, in the Phase 1 trial, a number of 191 healthy participants aged between 18 and 59 were vaccinated, where the group’s experimental shot showed no severe adverse reactions.
The most common adverse reactions reported by the participants in the trial were slight fatigue and redness, itching and swelling at the injection site, mild pain, but the candidates induced immune response.
“All the data obtained in this trial support the safety and immunogenicity of this inactivated vaccine and are encouraging with regard to further studies of its efficacy in the future,” the paper said.
According to reports, China has already vaccinated almost hundreds of thousands of essential workers and other groups, who are considered to be at high risk with other vaccines, even when the clinical trials had not been completed. This has raised safety concerns among the experts.
Currently, China has at least four experimental vaccines in the final stage of clinical trials.